Time to Tap Healthcare ETFs on Nvidia's AI Ambition?

Written by Emily J. Thompson, Senior Investment Analyst

JNJ+0.58%

HTEC-0.66%

ARKG-4.03%

Source: NASDAQ.COM

Updated: Apr 04 2024

0mins

Source: NASDAQ.COM

JNJ

$219.76+Infinity%1D

Analyst Views on JNJ

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

20 Analyst Rating

13 Buy

7 Hold

0 Sell

Moderate Buy

Current: 218.490

Low

190.00

Averages

218.50

High

240.00

Current: 218.490

Low

190.00

Averages

218.50

High

240.00

Guggenheim

Vamil Divan

Buy

maintain

$227 -> $240

2026-01-23

New

Reason

Guggenheim

Vamil Divan

Price Target

$227 -> $240

AI Analysis

2026-01-23

New

maintain

Buy

Reason

Guggenheim analyst Vamil Divan raised the firm's price target on Johnson & Johnson to $240 from $227 and keeps a Buy rating on the shares after the company reported "solid" Q4 results and provided initial 2026 guidance that was slightly ahead of sell-side estimates. Following the quarter, the firm is making several adjustments to its model, including raising near-term Tremfya estimates, accelerating Stelara erosion, and raising estimates for multiple newer products, says the analyst, who continues to identify J&J as a Top Picks in the large cap biopharma sector.

BofA

Jason Gerberry

Neutral

maintain

$220 -> $221

2026-01-22

New

Reason

BofA

Jason Gerberry

Price Target

$220 -> $221

2026-01-22

New

maintain

Neutral

Reason

BofA analyst Jason Gerberry raised the firm's price target on Johnson & Johnson to $221 from $220 and keeps a Neutral rating on the shares. The firm "modestly" increased its 2026 sales and EPS estimates following J&J's "solid" Q4 report, but thinks J&J's premium multiple "encapsulates the current consensus growth outlook" and notes that it is more cautious on the new product cycle.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JNJ

Unlock Now

Goldman Sachs

Asad Haider

Buy

maintain

$240 -> $250

2026-01-22

New

Reason

Goldman Sachs

Asad Haider

Price Target

$240 -> $250

2026-01-22

New

maintain

Buy

Reason

Goldman Sachs analyst Asad Haider raised the firm's price target on Johnson & Johnson to $250 from $240 and keeps a Buy rating on the shares. The setup is strong for another strong year with ongoing momentum in Innovative Medicine and MedTech, both of which demonstrated better-than-expected Q4 trends ahead of tailwinds in 2026 with multiple new product cycles continuing to unfold, the analyst tells investors in a research note.

Stifel

Rick Wise

Hold

maintain

$205 -> $220

2026-01-22

New

Reason

Stifel

Rick Wise

Price Target

$205 -> $220

2026-01-22

New

maintain

Hold

Reason

Stifel analyst Rick Wise raised the firm's price target on Johnson & Johnson to $220 from $205 and keeps a Hold rating on the shares following the company's Q4 sales outperformance and above-consensus initial 2026 guidance.

About JNJ

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.